Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence (LO-BOT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2021
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Overactive bladder; Urinary incontinence
- Focus Therapeutic Use
- Acronyms LO-BOT
- Sponsors Allergan
- 22 Nov 2020 Final results presented at the 50th Annual Meeting of the International Continence Society.
- 18 May 2020 Results assessing efficacy and safety of alternative Onabotulinumtoxina Injection Paradigm for Overactive Bladder, double blind and open label Results, presented at the 115th Annual Meeting of the American Urological Association
- 19 Feb 2019 Status changed from active, no longer recruiting to completed.